3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
9
Phase 2
5
Phase 1/2
3
Phase EARLY_PHASE1
1
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Breast Neoplasms
149
Lymphoma
60
Precursor Cell Lymphoblastic Leukemia-Lymphoma
47
Lymphoma, Large B-Cell, Diffuse
46
Leukemia
44
Lymphoma, Follicular
39
Lymphoma, Non-Hodgkin
35
Multiple Myeloma
33
Leukemia, Lymphocytic, Chronic, B-Cell
28
Leukemia, Myeloid, Acute
25
Burkitt Lymphoma
24
Neuroblastoma
21
Lymphoma, Large-Cell, Immunoblastic
16
Hodgkin Disease
16
Lymphoma, Mantle-Cell
14
Neoplasms
13
Triple Negative Breast Neoplasms
12
Lymphoma, B-Cell, Marginal Zone
11
Sarcoma
10
Inflammatory Breast Neoplasms
10
Rhabdomyosarcoma
8
Recurrence
8
Neoplasms, Plasma Cell
8
Myelodysplastic Syndromes
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Graft vs Host Disease
8
Lymphoma, T-Cell, Peripheral
7
Lymphoma, Large-Cell, Anaplastic
7
Leukemia, Biphenotypic, Acute
7
Lung Neoplasms
6
Interventions
Cisplatin
52
Radiotherapy
43
Cetuximab
30
Fluorouracil
27
pembrolizumab
19
Carboplatin
19
Docetaxel
14
Paclitaxel
8
Radiotherapy, Intensity-Modulated
7
Nivolumab
6
Methotrexate
6
Drug Therapy
6
Surgical Procedures, Operative
5
Chemotherapy, Adjuvant
5
Radiation
4
Neoadjuvant Therapy
4
Magnetic Resonance Spectroscopy
4
nimotuzumab
3
Taxes
3
Chemoradiotherapy
3
toripalimab
2
lenvatinib
2
epacadostat
2
durvalumab
2
dehydroftorafur
2
camrelizumab
2
avelumab
2
advexin
2
Specimen Handling
2
Radiotherapy, Conformal
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Squamous Cell Carcinoma of Head and Neck
×
Cyclophosphamide
×
Clear all
NCT01265849
2022-08-19
IT-MATTERS
CEL-SCI Corporation
Phase 3
Completed
928 enrolled
25 charts